Erasca, Inc. ERAS
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +293.55%
- 1 year
- +515.13%
- Market cap
- 5.12B
- EPS (ttm)
- -0.99
- Shares out
- 349.76M
- Forward P/E
- -23.49
- YTD return
- +293.55%
- 1-year return
- +515.13%
- Volume
- 3.80M
- Avg volume
- 4.43M
- Open
- 14.30
- Previous close
- 14.05
- Day's range
- 14.07 – 15.00
- 52-week range
- 2.20 – 22.47
- Beta
- 0.65
- Analysts
- Buy
- Price target
- 24.11 (+64.7%)
- Earnings date
- Nov 11, 2026
2Y +11.77 (+410.10%)
Key statistics
- Enterprise value
- 4.69B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -210.46M
- Total cash
- 268.74M
- Total debt
- 44.71M
- Return on equity
- -78.25%
- Short % of float
- 11.70%
- 50-day average
- 15.41
- 200-day average
- 15.02
Analyst view
Consensus: buy
- Target (low)
- 20.00
- Target (mean)
- 24.11
- Target (high)
- 33.00
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.13017.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.13013 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.11137 | -0.14 | -0.03 | -25.71% |
| May 11, 2026 | Mar 31, 2026 | -0.11152 | -0.60 | -0.49 | -438.02% |
| Mar 12, 2026 | Dec 31, 2025 | -0.11 | -0.10 | +0.01 | +9.09% |
| Nov 12, 2025 | Sep 30, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Aug 12, 2025 | Jun 30, 2025 | -0.12 | -0.12 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | main | Neutral | Neutral |
| Aug 13, 2026 | Guggenheim | main | Buy | Buy |
| Aug 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 20, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jul 14, 2026 | B of A Securities | main | Neutral | Neutral |
| Jun 4, 2026 | B of A Securities | up | Underperform | Neutral |
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- erasca.com
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS 
Erasca to Present at Upcoming Conferences in November 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS 
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS 
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next? 
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf 
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Your note
Sign in to keep a note on ERAS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARNER EBUN S | Officer | Sale | Mar 31, 2026 | 25,076 |
| MORRIS SHANNON R. M.D., PH.D. | Officer | Sale | Mar 3, 2026 | 0 |
| MULTANI PRATIK S | Director | Stock Gift | May 22, 2025 | 172,866 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.14% | 24,975,188 | 365.64M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.06% | 21,185,839 | 310.16M | Jun 29, 2026 |
| Blackrock Inc. | 6.05% | 21,154,146 | 309.70M | Jun 29, 2026 |
| RTW Investments LP | 5.13% | 17,946,754 | 262.74M | Jun 29, 2026 |
| Venrock Adviser, LLC | 5.12% | 17,891,812 | 261.94M | Jun 29, 2026 |
| State Street Corporation | 3.48% | 12,184,555 | 178.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.40% | 8,384,454 | 122.75M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.40% | 8,381,324 | 122.70M | Sep 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.99% | 6,954,600 | 101.82M | Jun 29, 2026 |
| SmallCap World Fund Inc | 1.97% | 6,886,446 | 100.82M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.64% | 5,734,875 | 83.96M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.95% | 3,334,921 | 48.82M | Jun 29, 2026 |